Positive clinical data for mipletamig provides a catalyst, but the $9.8M cash position and low equity raise suggest limited runway. Watch for Phase 2 regulatory interaction in early 2027 and potential partnership or financing needs to extend cash into key milestones.
Price Chart
Executive Summary
Aptevo Therapeutics reported Q2 2026 financial results and a business update, highlighting strong clinical data for lead candidate mipletamig in frontline AML (81% remission rate across 31 evaluable patients), a $1.5M non-dilutive grant for APVO451, and a 50/50 radiopharmaceutical collaboration with Niowave. Cash stood at $9.8M with only $0.6M raised via equity line during the quarter, underscoring a tight runway for a clinical-stage biotech with no revenue.
Key Facts
- Cash and cash equivalents of $9.8M as of June 30, 2026
- Raised $0.6M under Standby Equity Purchase Agreements with Yorkville in Q2 2026
- Mipletamig showed 87% clinical benefit rate and 81% remission rate in 31 evaluable frontline AML patients
- Secured $1.5M non-dilutive grant from Andy Hill CARE Fund for APVO451 IND-enabling work
- Entered 50/50 collaboration with Niowave for up to three radiopharmaceutical programs; Niowave took initial 7.9% equity stake
- Appointed Mary J. Janatpour, Ph.D. as SVP and Chief Scientific Officer
- No revenue or EPS reported for Q2 2026; filing is a business update with financial position only
Financial Impact
Cash position of $9.8M with minimal Q2 equity raise of $0.6M; no revenue or earnings disclosed
Risk Factors
- Limited cash runway of $9.8M may require dilutive financing before Phase 2 data
- Clinical-stage biotech with no approved products or revenue
- Early-stage clinical data may not replicate in larger trials
- Low market cap ($5M) increases volatility and financing risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-350537 |
| Document: apvo-ex99_1.htm | 0001193125-26-350537 |
| Document: 0001193125-26-350537-index-headers.html | 0001193125-26-350537 |
| Document: 0001193125-26-350537-index.html | 0001193125-26-350537 |
| Document: 0001193125-26-350537.txt | 0001193125-26-350537 |
| 8-K Data (Synthetic) | 0001193125-26-350537 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $1.73 | awaiting T+5 | — | $1.50 (−13.38%) |
Oct 23, 2026 3d ago | 8-K | $1.61 | awaiting T+5 | — | $1.50 (−6.83%) |
Oct 14, 2026 12d ago | 8-K | $1.73 $1.60 | ▼ −7.51% | ▼ −7.97% | $1.50 (−13.29%) |
Sep 24, 2026 4w ago | 8-K | $1.83 $1.76 | ▼ −3.83% | ▼ −3.41% | $1.50 (−18.03%) |
Sep 3, 2026 7w ago | 424B4 / 8-K | $1.71 $1.82 | ▲ +6.43% | ▲ +7.58% | $1.50 (−12.28%) |
Sep 3, 2026 7w ago | EFFECT | $1.71 $1.82 | ▼ −6.43% | ▼ −7.58% | $1.50 (+12.28%) |
Aug 14, 2026 10w ago | 8-K | $2.94 $2.68 | ▼ −8.84% | ▼ −7.48% | $1.50 (−48.98%) |
Jul 27, 2026 13w ago | 8-K | $4.21 $3.95 | ▼ −6.18% | ▼ −8.44% | $1.50 (−64.37%) |
Jun 30, 2026 16w ago | 8-K | $4.45 $4.51 | ▲ +1.35% | ▲ +1.09% | $1.50 (−66.29%) |
May 6, 2026 24w ago | 8-K | $4.86 $4.76 | ▼ −2.06% | ▼ −3.56% | $1.50 (−69.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers